ArticleDrug delivery and translational research2025
Innovative formulations for the ocular delivery of coenzyme Q10.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Immunological drivers of oxidative stress in glaucoma: implications for antioxidant therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Review of Therapeutic Potential of Coenzyme Q10 in Ophthalmology: Focus on Age-Related Macular Degeneration, Glaucoma, and Retinitis Pigmentosa.Antioxidants (Basel, Switzerland) · 2026Review
- Voriconazole nanosuspension-loaded ocular bilayer dissolving microneedle patch for the management of fungal keratitis.Drug delivery and translational research · 2026Article
- Dual-functional nanoparticle formulations for simultaneous intraocular pressure reduction and neuroprotection in glaucoma: a review.Nanomedicine (London, England) · 2026Review
- Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coenzyme Q10 (CoQ10) is a lipophilic antioxidant agent that plays a crucial role in the mitochondrial electron transport chain. The neuroprotective role of CoQ10, countering mitochondrial dysfunction and oxidative stress, suggests its potential as an adjuvant for ocular neurodegenerative diseases linked to retinal cell loss. However, despite its promising properties, ocular barriers pose challenges for effective delivery. Therefore, the present work aimed to identify new ocular delivery strategies to improve the therapeutic potential of CoQ10 by increasing its ocular bioavailability at the posterior segment and supporting its controlled release. Polymeric micelles of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) were selected as carriers for the loading of CoQ10, increasing its solubility and promoting its penetration through ocular tissues. After their characterization by dynamic light scattering (DLS) and small-angle X-ray scattering (SAXS), loaded micelles were applied to porcine sclera and choroid to confirm their ex vivo retention and permeation capacity. To ensure a controlled release, they were then loaded into a crosslinked polymer film, which was characterized in terms of mechanical properties, swelling degree and release profiles of TPGS and CoQ10. The biocompatibility of this platform was tested by the HET-CAM assay, and ex vivo studies confirmed its ocular potential.
Indexed as
Identifiers
39645537What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.